VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.
VBL has pioneered and is actively developing three novel platform technologies.
The Company’s most advanced program is the anti-cancer gene-therapy program, in which VB-111 is the lead candidate. VB-111 is positioned to potentially treat a wide range of solid tumors. VB-111 is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients. The mechanism of VB-111 combines blockade of tumor vasculature with an anti-tumor immune response. This mechanism may retain activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor.
VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VB-111 has also received an Orphan Designation for the treatment of ovarian cancer by the European Medicines Agency (EMA). More >>